Tryp Therapeutics Announces Q2 2021 Financial Results Post published:April 29, 2021 Post category:Press Release
Tryp Therapeutics Reports on Key Milestones for 2021 Post published:April 20, 2021 Post category:Press Release
Tryp Therapeutics Announces Listing on OTCQB and DTC Eligibility Post published:April 5, 2021 Post category:Press Release
Tryp Therapeutics Announces Amendment to Option Plan and Option Grant Post published:April 2, 2021 Post category:Press Release
Tryp Therapeutics Appoints Greg McKee as Chief Executive Officer Post published:April 1, 2021 Post category:Press Release
Tryp Therapeutics Announces Provisional Patent Filing For Improved Administration of Psychedelics Post published:March 18, 2021 Post category:Press Release
Tryp Therapeutics Appoints Luke Hayes as Chief Financial Officer Post published:March 9, 2021 Post category:Press Release
Tryp Therapeutics Announces Application to List on OTCQB Post published:March 4, 2021 Post category:Press Release
Tryp Therapeutics to Present at the Stifel GMP Healthcare Conference Post published:February 24, 2021 Post category:Press Release
Tryp Therapeutics Completes $2 Million Strategic Financing Post published:February 17, 2021 Post category:Press Release